Business & Industry

Eli Lilly and Company has entered into an agreement to acquire all outstanding shares of CrossBridge Bio in a transaction valued at up to $300m, structured through an upfront payment and additional milestone-based compensation linked to development progress. The...

AbbVie has entered into a global licensing agreement with China-based Haisco Pharmaceutical valued at up to $715 million, aiming to strengthen its presence in pain therapeutics. The Haisco deal grants AbbVie exclusive rights to develop, manufacture, and commercialize multiple...

Aragen has introduced ChemiSHE, positioning it as India’s first chemistry synthesis laboratory fully operated and led by women scientists. The facility was inaugurated on 8 April 2026 at the company’s Mallapur campus in Hyderabad, marking a targeted step by...

Danish pharmaceutical major Novo Nordisk has entered into a strategic collaboration with OpenAI to embed artificial intelligence across its drug development operations, with the stated goal of accelerating the delivery of new treatments. Announced on Tuesday, the initiative is...

Regeneron Pharmaceuticals has entered into a strategic agreement with Telix Pharmaceuticals to jointly develop next-generation oncology treatments, in a deal valued at up to $2.1 billion in milestone payments. The radiopharma collaboration will combine Regeneron’s antibody-based discovery capabilities with...

Biopharma companies are continuing to redirect production strategies toward Europe, even as U.S. policymakers attempt to strengthen domestic output through tariffs and onshoring measures. According to GlobalData, the latest data highlights a clear divergence in deal activity, with drug...

DeepCyte, a techbio company focused on advancing AI Drug Toxicology, has launched with $1.5 million in seed funding. The company is introducing two integrated solutions aimed at helping biopharma teams detect, predict, and explain drug toxicity directly in human...